Evotec SE's strategic deal with Sandoz AG involves the sale of Just - Evotec Biologics for approximately $350 million, positioning both companies for growth in the expanding biosimilars market.

Target Information

Evotec SE is a prominent life science company based in Hamburg, Germany, that specializes in innovative drug discovery and development. Through the integration of cutting-edge scientific research and advanced technologies, the firm aims to revolutionize the drug development process, reducing time scales and enhancing precision in delivering cures. The company's extensive expertise encompasses areas like small molecules, biologics, and cell therapies, supported by proprietary platforms, thus positioning Evotec as a leader in the biopharmaceutical sector.

With a workforce of over 4,800 professionals, Evotec operates multiple sites across Europe and the U.S., collaborating with more than 800 biotechnology firms, major pharmaceutical companies, academic institutions, and other healthcare stakeholders. Their goal is to improve drug accessibility and affordability, particularly through their subsidiary, Just - Evotec Biologics, which emphasizes sustainable biologics development.

Industry Overview in Germany

The German biopharmaceutical industry has witnessed consistent growth over the years, supported by a robust research environment and significant investment in life sciences. Germany's strategic investments in biotech and pha